以往发表的有关文献和药理学教科书中,认为保泰松和华法令竞争性地与血浆蛋白结合,使血浆中游离华法令浓度增高而引起出血。最近根据英国的M.Orme教授在卫生部委托上海市卫生局举办的临床药理学讲习班上作的题为“药物的相互作用”报告中认为,在试管实验中,保泰松可排斥华法令,临床上两者合用也往往容易起出血倾向,但事实上保泰松并不影响华法令与血浆蛋白的结合,而是影响了华法令的代谢,M.Orme Previously published textbooks on the literature and pharmacology, which consider phenylbutazone and warfarin competitively bind to plasma proteins, causing increased plasma concentrations of free warfarin to cause bleeding. According to a recent report entitled “Interactions of drugs” by Professor M.Orme of the UK in a seminar on clinical pharmacology commissioned by the Shanghai Health Bureau commissioned by the Ministry of Health, Phenylbutazone may exclude Warfarin, clinical combination of the two often tend to play a tendency to bleeding, but in fact Phenylbutazone does not affect the combination of warfarin and plasma proteins, but affects the metabolism of warfarin, M.Orme